SeeThruEquity Initiates Coverage on AzurRx BioPharma, Inc. (NASDAQ CM: AZRX) with a Price Target of $10.00

NEW YORK, NY / ACCESSWIRE / January 30, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has initiated coverage on AzurRx BioPharma, Inc. (NASDAQ: AZRX) with a 12-month price target of US $10.00.

The report is available here: AZRX Initiation Report.

We initiate coverage of AzurRx BioPharma (Nasdaq CM: AZRX, “AzurRx”) with a price target of $10.00. With headquarters in Brooklyn, NY, and scientific offices in Langlade, France, AzurRx is a clinical-stage biotechnology firm developing non-systemic, recombinant protein therapies for treatment of gastrointestinal and infectious diseases. The company’s lead candidate is MS1819, a Phase 2 autologous yeast recombinant lipase (Yarrowia lipolytica LIP2) being developed to target the $1.5 billion global market for treating Exocrine Pancreatic Insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). AzurRx’s second program is AZX1101, a pre-clinical beta-lactamase for prevention of hospital infections from resistant bacterial strains. AzurRx has several upcoming clinical events in 2018, including final data from its ongoing Phase 2 MS1819 clinical trial, initial data expected by year-end 2018 from a new Phase 2 CF trial for MS1819, and proof of concept data for AZX1101. We see the company as a speculative clinical-stage biotechnology company with an intriguing risk/reward tradeoff and several potential catalysts on the horizon.

Highlights from the report include:

Lead candidate MS1819 targeting $1.5 billion market for EPI

AzurRx is developing a portfolio with candidates addressing large market opportunities in gastrointestinal and infectious diseases. The company’s lead product candidate, MS1819 for EPI, promises significant improvements over the current standard of care, which consists of porcine pancreatic extracts (PPEs). MS1819 is designed to improve significantly the safety and efficacy of lipase substitutes for EP patients versus the standard of care – specifically in the highly acidic intestine environment – while materially reducing the patient’s pill burden. If approved, MS1819 would seek to acquire share in an existing $1.5 billion global market for treating EPI in patients with CF and CP by reducing the risk of animal viral contamination transference, improving efficacy, and significantly improving the quality of life and treatment compliance of these patients by lowering the pill burden from 25 to 40 pills per day to 5 to 8 pills per day. The company is currently conducting a Phase 2a dose escalation study of MS1819 for EPI in CP patients, and reported encouraging initial results in 3Q17; final data from the trial is expected during 2018.

AZX-1101 addresses multi-billion dollar opportunity to prevent hospital-acquired infections

AzurRx is also developing AZX1101, a pre-clinical stage recombinant-beta-lactamase combination of bacterial origin for the prevention of nosocomial (hospital-acquired) infections, such as clostridium difficile (C Diff), and antibiotic-associated diarrhea. Though in early stages of development, AZX1101 targets a significant health issue as there are 1.7mn hospital-associated infections in the United States each year with an annual cost of $4.5 billion to $10 billion annually.

Initiating coverage of AzurRx with price target of $10.00

We initiate coverage of AzurRx with a price target of $10.00. We view AzurRx as a speculative company in the biotechnology sector offering a noteworthy risk/reward tradeoff, as the company targets multi-billion dollar opportunities to treat gastrointestinal and infectious disease. AzurRx has multiple catalysts ahead as the company expects to report clinical data from Phase 2 studies of MS1819 and proof-of-concept data for AZX1101 in 2018.

Please review important disclosures on our website at www.seethruequity.com.

About AzurRx BioPharma, Inc.

AzurRx BioPharma, Inc. (NASDAQ: AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company’s lead development program, and additional early-stage research is being conducted for the prevention of hospital-acquired infections. The company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France. www.Azurrx.com.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high-quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information visit: www.seethruequity.com.

Contact:

SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 487312